Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | ABL2 | P42684 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672219 | 1.00 | EGFR (0.57) | EGFRABL1ABL2AURKAERBB2 | |
| Hydrochloric Acid SCHEMBL7218016 | 0.98 | EGFR (0.55) | EGFRABL1ABL2AURKAERBB2 | |
| SCHEMBL30159366 | 0.79 | LIMK1 (0.59) | EGFRABL1ABL2ERBB2LIMK1 | |
| SCHEMBL3473013 | 0.79 | LIMK1 (0.59) | EGFRABL1ABL2ERBB2LIMK1 | |
| SCHEMBL6881920 | 0.79 | AURKA (0.56) | EGFRABL1ABL2AURKAALK | |
| SCHEMBL31219008 | 0.79 | AURKA (0.56) | EGFRABL1ABL2AURKAALK | |
| SCHEMBL7497481 | 0.79 | AURKA (0.45) | AURKAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13209220 | 0.78 | EGFR (0.57) | EGFRABL1ABL2ERBB2LIMK1 | |
| SCHEMBL6884961 | 0.78 | EGFR (0.57) | EGFRABL1ABL2AURKAERBB2 | |
| SCHEMBL3115940 | 0.77 | AURKA (0.48) | AURKAMAPTCHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217212-A1 | MAC1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024199444-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2023001133-A1 | PRMT5 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001133-A1 | PRMT5 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-8999988-B2 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-04-07 | — | — | US | disclosed |
| US-8618121-B2 | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2013-11-14 | — | — | US | disclosed |
| US-8552018-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110212929-A1 | Protein Kinase Inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2011-09-01 | — | — | US | disclosed |
| WO-2011056739-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7205396-B2 | Benzodeazaadenine derivative base and electronic material containing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7205396-B2 | Benzodeazaadenine derivative base and electronic material containing the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1678166-A2 | PROTEIN KINASE INHIBITORS | Arizona Board of Regents on behalf of The University of Arizona (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050277658-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050239794-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050239793-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227992-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005037825-A2 | PROTEIN KINASE INHIBITORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227992-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
| US-20050277658-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
| US-20050239794-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
| US-20050239793-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
| US-20130302303-A1 | PROTEIN KINASE INHIBITORS | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
| US-20110212929-A1 | Protein Kinase Inhibitors | CDK2, MAP3K1, MAP3K2 | EGFR 957/4885ABL1 569/4885ABL2 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.